Bionano Genomics Statistics
Share Statistics
Bionano Genomics has 3.1M
shares outstanding. The number of shares has increased by -96.05%
in one year.
| Shares Outstanding | 3.1M |
| Shares Change (YoY) | -96.05% |
| Shares Change (QoQ) | -97.32% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 597.41K, so 21.86% of the outstanding
shares have been sold short.
| Short Interest | 597.41K |
| Short % of Shares Out | 21.86% |
| Short % of Float | 21.87% |
| Short Ratio (days to cover) | 1.86 |
Valuation Ratios
The PE ratio is -0.29 and the forward
PE ratio is -0.47.
Bionano Genomics's PEG ratio is
0.
| PE Ratio | -0.29 |
| Forward PE | -0.47 |
| PS Ratio | 1.05 |
| Forward PS | 0.1 |
| PB Ratio | 0.91 |
| P/FCF Ratio | -0.47 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Bionano Genomics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06,
with a Debt / Equity ratio of 0.77.
| Current Ratio | 1.06 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | -0.28 |
| Debt / FCF | -0.4 |
| Interest Coverage | -359.8 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $314,040.82 |
| Profits Per Employee | $-1,143,030.61 |
| Employee Count | 98 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | 33K |
| Effective Tax Rate | -0.03% |
Stock Price Statistics
The stock price has increased by -93.48% in the
last 52 weeks. The beta is 2.37, so Bionano Genomics's
price volatility has been higher than the market average.
| Beta | 2.37 |
| 52-Week Price Change | -93.48% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 15.47 |
| Relative Strength Index (RSI) | 43.7 |
| Average Volume (20 Days) | 141,906 |
Income Statement
In the last 12 months, Bionano Genomics had revenue of 30.78M
and earned -112.02M
in profits. Earnings per share was -60.05.
| Revenue | 30.78M |
| Gross Profit | 380K |
| Operating Income | -103.98M |
| Net Income | -112.02M |
| EBITDA | -97.47M |
| EBIT | -111.69M |
| Earnings Per Share (EPS) | -60.05 |
Full Income StatementBalance Sheet
The company has 9.17M in cash and 27.3M in
debt, giving a net cash position of -18.12M.
| Cash & Cash Equivalents | 9.17M |
| Total Debt | 27.3M |
| Net Cash | -18.12M |
| Retained Earnings | -693.23M |
| Total Assets | 76.67M |
| Working Capital | 2.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -68.92M
and capital expenditures -103K, giving a free cash flow of -69.03M.
| Operating Cash Flow | -68.92M |
| Capital Expenditures | -103K |
| Free Cash Flow | -69.03M |
| FCF Per Share | -37 |
Full Cash Flow StatementMargins
Gross margin is 1.23%, with operating and profit margins of -337.87% and -363.98%.
| Gross Margin | 1.23% |
| Operating Margin | -337.87% |
| Pretax Margin | -363.87% |
| Profit Margin | -363.98% |
| EBITDA Margin | -316.7% |
| EBIT Margin | -337.87% |
| FCF Margin | -224.28% |
